Status:
UNKNOWN
TACE Combined With Penpulimab and Anlotinib for Advanced HCC
Lead Sponsor:
Zhongda Hospital
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the optimum inter...
Detailed Description
The efficacy and safety of transarterial chemoembolization (TACE) combined with penpulimab and anlotinib in the treatment of advanced hepatocellular carcinoma (HCC) remain unknown. This is a multicent...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Pathologically or clinically diagnosed HCC patients;
- Age of 18-80;
- Barcelona Clinic Liver Cancer (BCLC) stage C (ie, China Liver Cancer Staging (CNLC) stage III);
- with expect survival ≥ 3 months;
- with obtained informed consent;
- will receive penpulimab and anlotinib combined with or without TACE.
- Exclusion criteria:
- Contraindications of penpulimab and anlotinib;
- Child-Pugh C;
- Key information (such as imaging, liver function, Eastern Cooperative Oncology Group(ECOG) score, etc.) missing.
Exclusion
Key Trial Info
Start Date :
October 12 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT05344924
Start Date
October 12 2022
End Date
March 31 2024
Last Update
December 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongda Hospital Affiliated to Southeast University
Nanjing, Jiangsu, China, 210009